The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Thromboplastin

Thromboplastin

Thromboplastin is a complex of phospholipids and proteins that initiates the extrinsic pathway of the blood coagulation cascade.
It is found in the membranes of many cell types, particularly those of the vascular endothelium and is released upon tissue injury, triggering the formation of a fibrin clot.
Thromboplastin plays a crucial role in maintaining hemostasis and preventing excessive bleeding.
Researchers can utilize PubCompare.ai to optimize thromboplastin protocols by identifying and comparing the best methods from published literature, pre-prints, and patents, enhancing the reproducibility and accuracy of their thromboplastin assays and ensuring reliable and effecient research outcomes.

Most cited protocols related to «Thromboplastin»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Beer CCL4 protein, human Cortical Hemodynamic Responses deoxyhemoglobin Head Heart Hemodynamics Hemoglobin Oxyhemoglobin Radionuclide Imaging Respiratory Rate Scalp Spectroscopy, Near-Infrared Speech Thromboplastin Vision Voluntary Workers
All research was approved and conducted under the guidelines of the Human Research Ethics Committee at the University of New South Wales (HREC 07261). The study cohort included 37 schizophrenia/schizoaffective disorder cases and 37 matched controls (Table 1). Controls were selected prior to RNA extraction based on the following parameters (in descending order of importance for matching), brain pH (±1), age at death (within 10 years), and PMI (within 10 hours). Other factors such as hemisphere, gender, time in freezer and agonal state were matched on a stratum (group-wise) basis. Details of brain collection and determination of clinical and tissue factors can be found in Supplementary Materials and Methods, and in Tables 5S and 6S.
Publication 2010
Brain Ethics Committees, Research Homo sapiens Schizophrenia Thromboplastin

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Adult Aluminum Biological Assay BLOOD Blood Platelet Disorders Blood Platelets Calculi Deceleration Dextran Donors Electricity Ethics Committees, Research Gel Chromatography Hemodynamics Human Volunteers Medical Devices physiology Platelet-Rich Plasma Platelet Activation Sepharose Systole Thromboplastin Torque Viscosity Voluntary Workers
We trained our cross-tissue gene expression imputation model using genotype and normalized gene expression data from 44 tissues in the GTEx project (version V6p, dbGaP accession code: phs000424.v6.p1)3 (link). Sample sizes for different tissues ranged from 70 (uterus) to 361 (skeletal muscle). SNPs with ambiguous alleles or minor allele frequency (MAF) < 0.01 were removed. Normalized gene expressions were further adjusted to remove potential confounding effects from sex, sequencing platform, top three principal components of genotype data, and top probabilistic estimation of expression residuals (PEER) factors77 . As previously recommended17 , we included 15 PEER factors for tissues with N < 150, 30 factors for tissues with 150 ≤ N < 250, and 35 factors for tissues with N ≥ 250. All covariates were downloaded from the GTEx portal website (URLs). We applied a 5-fold cross-validation for model tuning and evaluation. Specifically, we randomly divided individuals into five groups of equal size. Each time, we used three groups as the training set, one as the intermediate set for selecting tuning parameters, and the last one as the testing set for performance evaluation. Squared correlation between predicted and observed expression (i.e. R2) was used to quantify imputation accuracy. For each model, we selected gene-tissue pairs with FDR < 0.05 for downstream testing. External validation of imputation accuracy was performed using whole-blood expression data from 421 samples in the 1000 Genomes Project (GEUVADIS consortium)32 (link) and the CommonMind consortium33 (link), which collected expression in across multiple regions from > 1,000 postmortem brain samples (mainly corresponding to Brain_Frontal_Cortex_BA9 in GTEx) from donors with schizophrenia, bipolar disorder, and individuals with no neuropsychiatric disorders. For CommonMind data, we focused our analysis on 147 controls with no neuropsychiatric disorders. Average improvements in R2 in both external validation datasets are shown in Supplementary Figure 4. Although not statistically significant due to the limited sample size, the accuracy of the cross-tissue method was consistently higher than that of the single-tissue approach in different quantiles. Furthermore, comparing the tissue-tissue similarity based on the observed and imputed gene expressions indicated that cross-tissue imputation removed stochastic noises in the expression data without losing tissue-specific correlational patterns (Supplementary Note; Supplementary Figure 56).
Publication 2019
Alleles Autopsy Bipolar Disorder BLOOD Brain Donors Gene Expression Genes Genome Genotype Lobe, Frontal Schizophrenia Single Nucleotide Polymorphism Skeletal Muscles Thromboplastin Tissues Uterus
This model provides a total stasis environment and results in the most severe vein wall reaction to thrombosis of the models discussed.8 (link),17 (link),20 (link),23 Studies in rats suggest that after IVC ligation a combination of stasis-induced vein wall injury and enhanced tissue factor expression in endothelial cells and leukocytes produce thrombosis.42 (link) In this model, mice are anesthetized and a midline laparotomy is performed. The small bowel is exteriorized and placed on a moistened gauze pad to the animal’s left. The infrarenal IVC is identified and all side branches are ligated with nonreactive 7-0 Prolene suture. Posterior venous branches are cauterized.23 A 7-0 Prolene suture is tied down on the IVC, caudal to the left renal vein. This model has been widely used by our group for the study of venous thrombosis.8 (link),17 (link),20 (link),21 (link) It provides reproducible thrombus weights beginning at 3 hours and extending to 21 days, for most mouse strains. It has proven valuable in the study of interactions between the vein wall and thrombus during the progression from acute to chronic inflammation and remodeling of the vein wall. Disadvantages include the lack of blood flow. A technical pitfall unique to this procedure is the potential to induce initial hypotension. However, compensation by vertebral veins is observed and the survival rate for this model is around 95%, based on our laboratory’s observations. In addition, the IVC cannot reopen because of the ligature. This model cannot reproduce the clinical scenario where a thrombus is nonocclusive, but it can mimic complete occlusion (Figure 2 and Table). As a guideline, data from our laboratories in C57BL/6 mice shows, approximate thrombus weights (IVC+thrombus at harvest), of 33 mg at day 2, 29 mg at day 6, and 18 mg at day 14.
Publication 2012
Animals Blood Circulation Dental Occlusion Disease Progression Endothelial Cells Inflammation Injuries Intestines, Small Laparotomy Leukocytes Ligation Ligature Mice, Inbred C57BL Mus Prolene Rattus norvegicus Strains Sutures Thromboplastin Thrombosis Thrombus Vein, Renal Veins Venous Thrombosis Vertebra

Most recents protocols related to «Thromboplastin»

The next experiments were approved by an appropriate institution. In addition to this, all methods were performed following the relevant guidelines and regulations including ARRIVE guidelines. The in vitro anticoagulant activity was examined as the increase in the coagulation period of human blood serum in the existence of 15 µg of UcB5 protease/ml15 (link). Exactly, 100 µl of blood serum was vortexed with equivalent volumes of each thromboplastin and kaolin. After 2 min incubation at 37 °C in a water bath, exactly 100 µl of 0.3% (w/v) CaCl2 and 100 µl of the enzyme were added. The clotting time in the presence of the enzyme was then determined in comparison with blanks containing an equivalent amount of physiological saline instead of the purified enzyme.
Publication 2023
Anticoagulants Bath BLOOD clotting enzyme Coagulation, Blood Enzymes Homo sapiens Kaolin Peptide Hydrolases physiology Saline Solution Serum Thromboplastin
INR levels in the fingertip capillary blood from the patients were measured using CoaguChek XS Plus. Simultaneously, venous blood samples were collected into a tube containing 3.2% buffered sodium citrate. The tubes were transferred to a conventional laboratory and centrifuged at 1,550×g for 15 minutes. The plasma obtained after centrifugation was used to measure the INR by a conventional laboratory test using a standard coagulation analyzer ACL TOP 750.
All coagulation factor tests were performed using the ACL TOP 750 analyzer. The coagulation factors were measured by a PT-based clotting test using HemosIL RecombiPlasTin reagent (ISI 1.0) for factors II, V, VII, and X (Instrumentation Laboratory, Lexington, MA, USA) and by an activated partial thromboplastin-based clotting test using SynthASil reagent for factors VIII, XI, XI, and XII (Instrumentation Laboratory SpA). Fibrinogen was measured using the Fibrinogen-C XL kit (Instrumentation Laboratory SpA). Proteins C and S were also tested using the ACL TOP 750 analyzer.
Thrombin generation was measured as previously described [8 (link)]. Briefly, 20 μL of reagent containing tissue factor at a final concentration of 1 or 5 pmol/L, as well as phospholipids or thrombin calibrators, was distributed in each well of 96-well plates, and 80 μL of test plasma was added. After the addition of 20 μL of fluorogenic substrate in HEPES buffer containing CaCl2, fluorescence was measured using a Fluoroskan Ascent fluorometer (Thermo Labsystems, Helsinki, Finland), and thrombin generation curves were calculated using the Thrombinoscope software (Thrombinoscope, Maastricht, the Netherlands). The curves were analyzed using parameters that describe the initiation, propagation, and termination phases of thrombin generation, including lag time, peak thrombin, time to peak, and ETP.
Publication 2023
Blood Coagulation Factor Buffers Capillaries Centrifugation Coagulation, Blood Factor VIII Fibrinogen Fluorescence Fluorogenic Substrate HEPES Patients Phospholipids Plasma Protein C Prothrombin Sodium Citrate Tests, Blood Coagulation Thrombin Thromboplastin Veins
Blood samples were collected into 3 mL tubes (Sarstedt) containing 3.2% citrate. The samples were processed within 1 hour after the blood collection, centrifuged at 2000 g for 20 minutes to prepare platelet-poor plasma, aliquoted, and immediately stored at −80 °C. The aliquots were thawed directly before the analysis. Anti-Xa activity was determined with a chromogenic substrate and a bovine FXa (Hyphen BioMed), and a chromogenic anti-IIa assay with human thrombin (Hyphen BioMed) was used to measure anti-IIa activity. The FVIII activity was assessed by a one-stage clotting test (Siemens Healthineers). In addition, activities of D-dimer, prothrombin fragments, VWF antigen, and VWF (all purchased from Siemens Healthineers) were measured on a BCS analyzer (Siemens Healthineers). The TG assay was carried out on a Fluoroscan Ascent (Fisher Scientific) at a 390/460-nm wavelength using a calibrated automated thrombogram (Diagnostica Stago) activated with 5-pM tissue factor.
Publication 2023
Antigens azo rubin S Biological Assay BLOOD Blood Platelets Cattle Chromogenic Substrates Citrates Heparin, Low-Molecular-Weight Homo sapiens Plasma Prothrombin Tests, Blood Coagulation Thrombin Thromboplastin
The antibiotic-supplemented diets were fed to the flies at both larval and adult stages (L+/A+), or only at the larval stage (L+/A−). For the latter, the pupae were collected and rinsed with ddH2O twice before transferring to antibiotic-free vials. To test the maternal or paternal effects, the newly emerged males and females were crossed with their WT partners for 1–2 weeks. The F1 generation was reared on the antibiotic-free diet. Then, 100 eggs (0–6 h collection) and 10 adult females (1 day old) from each cross were collected as test samples for ELISA (Elabscience Biotechnology). In addition, 10 WT adult females (1 day old) from antibiotic-free and Tet-100-containing diets were collected as negative and positive controls, respectively. Three biological replicates were used for each cross and control. A measure of 400 µL of trichloroacetic acid solution (1%) and beads (Lysing Matrix D Bulk, Cat. 6540-434, MPbio, France) were added to the sample tube, and the tissues were homogenized using a Precellys 24 homogenizer (for 20 s at 6000 rpm). The sample tubes were centrifuged at 4,000 g for 10 min at room temperature. Then, the supernatant (27.5 µL) was mixed with reconstitution buffer (82.5 µL), and 50 µL of the mixture was used for analysis. The standard solution (1.0 ppm) was diluted according to the manufacturer’s instructions. A measure of 50 µL of diluted standard solution and sample mixture was added per well of the pre-coated 96-well microtiter plate in duplicate; 50 µL of the antibody working solution was added to each well, and the plate was covered with a lid, gently oscillated for 5 s, and incubated with shading light at 37°C for 30 min. After incubation, the microplate wells were washed six times with 250 µL/well of washing buffer, 100 μL/well of streptavidin–horseradish peroxidase (HRP conjugate) was added, and the plate was incubated at 37°C for 30 min in the dark. Then, the plate was washed again as described previously, and 50 μL of each substrate reagent A and B was added sequentially per well. After incubation at 37°C in the dark for 15 min, the reaction was stopped by adding 50 μL/well of stop solution. Optical density (OD) at 450 nm and 630 nm of each well was measured as reference wavelength (TECAN microplate reader). The concentrations (ppb) were calculated as the OD value measured at 630 nm subtracted from that measured at 450 nm. The absorbance percentage was calculated using the following formula: absorbance (%) = A/A0 × 100% (A: average absorbance of the standard solution or sample; A0: average absorbance of 0 ppb standard solution). The average absorbance value from duplicate wells was added to the standard curve. The concentration calculated from the standard curve was multiplied by 8 (the dilution factor for the pretreatment of tissue/egg samples according to the manual) for the final concentration of the samples.
Publication 2023
Adult Antibiotics Biopharmaceuticals Buffers Diet Dietary Fiber Diptera Enzyme-Linked Immunosorbent Assay Females Immunoglobulins Larva Light Males Paternal Inheritance Pupa Streptavidin Technique, Dilution Thromboplastin Tissues Trichloroacetic Acid Woman

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Biological Assay Contraceptives, Oral Donors Fibrin Plasma Plasmin PLAT protein, human Proteolysis Thrombin Thromboplastin Times, Reptilase Woman

Top products related to «Thromboplastin»

Sourced in Germany, United States, Sweden, United Kingdom
Innovin is a lab equipment product by Siemens. It is a thromboplastin reagent used for the determination of prothrombin time (PT) in plasma samples.
Sourced in Switzerland, United States
Z-Gly-Gly-Arg-AMC is a laboratory reagent used for the fluorimetric assay of proteases. It is a peptide substrate that, when cleaved by a protease, releases a fluorescent compound (AMC) that can be detected and quantified.
Sourced in Germany, United States, United Kingdom
The Dade Innovin is a laboratory coagulation reagent used to measure prothrombin time (PT) in human plasma samples. It contains thromboplastin, a key component in the extrinsic pathway of the coagulation cascade. The Dade Innovin provides a reliable and consistent means of assessing the activity of the coagulation system.
Sourced in United States
Thromboplastin D is a reagent used in prothrombin time (PT) tests. It contains thromboplastin, a substance that activates the extrinsic pathway of the coagulation cascade. The core function of Thromboplastin D is to provide the necessary components to measure the clotting time of a blood sample, which is an indicator of the functioning of the prothrombin system.
Sourced in United States, Finland, France, Japan, Belgium, United Kingdom, Australia, Spain, China, Germany
The Fluoroskan Ascent is a microplate fluorometer and luminometer designed for sensitive and versatile fluorescence and luminescence detection. It is capable of measuring a wide range of fluorescent and luminescent assays in multi-well microplates.
Sourced in United States, Italy
Recombiplastin is a laboratory reagent used in coagulation assays. It contains recombinant human tissue factor and synthetic phospholipids, which are necessary for the activation of the extrinsic pathway of the coagulation cascade.
Sourced in Finland, United States
The Fluoroskan Ascent fluorometer is a multi-function instrument designed for fluorometric and luminometric analysis. It measures fluorescence and luminescence in microplates, supporting a wide range of application areas.
Sourced in United States, United Kingdom, Brazil, Germany, Canada, France, Spain, Italy, Switzerland, Australia, Sweden, Belgium, New Zealand, Denmark, Mexico, Jersey, South Sudan, Austria, Japan
The BD Vacutainer is a blood collection system used to collect, process, and preserve blood samples. It consists of a sterile evacuated glass or plastic tube with a closure that maintains the vacuum. The Vacutainer provides a standardized method for drawing blood samples for laboratory analysis.
Sourced in United States, Canada, Japan
ExoQuick is a proprietary precipitation reagent designed to isolate extracellular vesicles, including exosomes, from various biological samples. It is a fast and simple method for the concentration and purification of exosomes.
Sourced in Germany, France
Actilyse is a laboratory equipment product manufactured by Boehringer Ingelheim. It is a recombinant tissue plasminogen activator (rt-PA) used for the in vitro analysis of fibrinolytic systems.

More about "Thromboplastin"